
|Videos|August 30, 2022
Comparing Approved Options for Androgen Inhibition in the mCSPC Setting
Author(s)Marc Matrana, MD
Discussion centered around androgen receptor inhibition/androgen synthesis inhibition and comparison of available, approved options for each.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
4
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
5
































